Publication | Closed Access

A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer

Phase Ib StudyDual InhibitorIr Tyrosine KinaseOncologyGastrointestinal OncologyMedicineColorectal CancerPathologyPharmacologyRadiation Oncology